USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
ARGOLYN BIOSCIENCE, INC.
Address:
ARGOLYN BIOSCIENCE, INC.
2750 Speissegger Drive, Suite 110
NORTH CHARLESTON, SC
Phone:
(843) 266-0851
URL:
N/A
EIN:
352167082
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $163,945.00 1
SBIR Phase II $1,345,456.00 1
STTR Phase I $264,745.00 2

Award List:

NON-NATURAL AMINO ACIDS IN PEPTIDE DRUG DEVELOPMENT

Award Year / Program / Phase:
2002 / STTR / Phase I
Award Amount:
$125,279.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL UNIVERSITY OF SOUTH CAROLINA
RI Contact:
N/A
Abstract:
Argolyn Bioscience Inc. is an early stage biotechnology company that creates novel peptide drugs and diagnostics with greatly improved intrinsic pharmaceutical properties through substitution of non-natural amino acid analogues for arginine (Arg) or lysine (Lys). In proof-of concept studies thus… More

NOVEL NEUROTENSIN ANALOGS AS ANTISCHIZOPRENICS

Award Year / Program / Phase:
2002 / STTR / Phase I
Award Amount:
$139,466.00
Agency:
HHS
Principal Investigator:
Research Institution:
MEDICAL UNIVERSITY OF SOUTH CAROLINA
RI Contact:
N/A
Abstract:
DESCRIPTION (provided by applicant): The brain peptide neurotensin (NT) and its active derivative NT [8-13] function as endogenous neuroleptics. Stable NT derivatives that cross the blood brain barrier therefore have significant potential for development as a new class of non-dopamineric… More

Novel Neurotensin Analogs as Antischizophrenics

Award Year / Program / Phase:
2005 / SBIR / Phase II
Award Amount:
$1,345,456.00
Agency:
HHS
Principal Investigator:
Thomas A. Dix – (843) 284-2202
Abstract:
DESCRIPTION (provided by applicant): Low levels of the brain peptide neurotensin (NT) have been linked to schizophrenia. Hence, stable NT receptor agonists that cross the blood brain barrier have significant potential for development as a new class of antipsychotics that may not have the adverse… More

Development of Neurotensin-based Analgesics

Award Year / Program / Phase:
2006 / SBIR / Phase I
Award Amount:
$163,945.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Chronic, neuropathic pain is one of the most important unmet medical needs in the United States, affecting tens to hundreds of millions of people nationwide at some time during their lives. Novel therapeutic approaches are desperately needed. The brain peptides… More